{"id":7284,"date":"2025-12-27T10:18:19","date_gmt":"2025-12-27T09:18:19","guid":{"rendered":"https:\/\/jacked.sk\/obchod\/ara-290-10mg\/"},"modified":"2026-08-21T14:15:50","modified_gmt":"2026-08-21T12:15:50","slug":"ara-290-10mg","status":"publish","type":"product","link":"https:\/\/dev.jacked.sk\/en\/research-on-tissue-regeneration-and-healing\/ara-290-10mg\/","title":{"rendered":"ARA-290 10 mg"},"content":{"rendered":"<div class=\"row read-more\"  id=\"row-1211885015\">\n\n\t<div id=\"col-1275685941\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h1>ARA-290 10 mg \u2013 Erythropoietin Derivative for Research into Neuroprotection and Regeneration<\/h1>\n<p>\u26a0\ufe0f <strong>Legal Notice:<\/strong> ARA-290 is intended exclusively for scientific and research purposes. It is not intended for human use as a medication, dietary supplement, or cosmetic product. Sale exclusively to individuals over the age of 18.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-321289184\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>What is ARA-290 (cibinetide)?<\/h2>\n<p>ARA-290, also known as <strong>cibinetide<\/strong>, is <strong>a cyclic peptide composed of 11 amino acids<\/strong> derived from a structural region of erythropoietin (EPO). It was developed and patented by <strong>Araim Pharmaceuticals<\/strong> (USA) with the aim of isolating the tissue-protective properties of EPO from its undesirable hematopoietic effects.<br \/>\nErythropoietin is an endogenous glycoprotein hormone primarily responsible for regulating red blood cell production (erythropoiesis). However, research has revealed that EPO also acts through another receptor system\u2014 <strong>the INNATE REPAIR RECEPTOR (IRR)<\/strong> \u2014thereby mediating tissue-protective and anti-inflammatory effects independent of erythropoiesis.<br \/>\nARA-290 was designed to <strong>selectively activate IRR without binding to the classical erythropoietin receptor (EPOR)<\/strong>, thereby avoiding thrombotic and other risks associated with its hematopoietic effect. This selectivity makes ARA-290 an attractive subject for research in longer-term non-hematological studies.<br \/>\nImportant: <strong>ARA-290 is not approved as a drug<\/strong> in the European Union or the United States. The available data are derived from preclinical studies and Phase 1\u20132 clinical trials.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1838054899\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Key feature: tissue protection without erythropoietin activity<\/h2>\n<p>The most significant research aspect of ARA-290 is its ability to activate <strong>EPO\u2019s tissue-protective signaling pathways without stimulating erythropoiesis<\/strong>. This distinction is crucial for several reasons: <\/p>\n<ul>\n<li><strong>Long-term administration of erythropoietin<\/strong> increases hematocrit (the percentage of red blood cells in the blood), which increases blood viscosity and the risk of thromboembolic complications.<\/li>\n<li><strong>ARA-290 does not present these risks<\/strong> \u2014no stimulation of erythropoiesis or changes in hematocrit were observed in preclinical and Phase 1\u20132 clinical studies.<\/li>\n<li>This feature makes it possible to study <strong>longer-term research protocols<\/strong> without hematological concerns, which is valuable from a scientific standpoint.<\/li>\n<\/ul>\n<p>Research has identified IRR (Innate Repair Receptor) as a heterodimer consisting of EPOR and the beta-common chain (\u03b2c, also known as CD131). This receptor is expressed primarily in non-neural and neural tissues (not in erythroid progenitors), which explains the tissue selectivity of ARA-290.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-768040080\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Mechanism of Action \u2013 INNATE REPAIR RECEPTOR (IRR)<\/h2>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1402529564\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Activation of a tissue-protective cytokine receptor<\/h3>\n<p>ARA-290 binds to and activates <strong>the INNATE REPAIR RECEPTOR (IRR)<\/strong>, also known as TPCR (Tissue Protective Cytokine Receptor). This receptor is a heterodimer composed of: &#8211; <strong>Erythropoietin receptor (EPOR)<\/strong> \u2013 one subunit &#8211; <strong>Beta-common chain (\u03b2c, CD131)<\/strong> \u2013 the second subunit, shared with receptors for IL-3, IL-5, and GM-CSF<br \/>\nActivation of IRR triggers intracellular signaling cascades involving the PI3K\/Akt and JAK2\/STAT5 pathways, which are associated with anti-apoptotic and anti-inflammatory effects in various tissues.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-991014921\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Department of Tissue-Protective and Hematopoietic Effects of EPO<\/h3>\n<p>Conventional erythropoietin acts through homodimeric EPOR (two EPOR subunits), leading to hematopoietic activation. ARA-290 was structurally designed to interact preferentially with IRR (the EPOR\u2013\u03b2c heterodimer), rather than with homodimeric EPOR. This selective targeting is the basis for its distinct pharmacological profile.<br \/>\n<em>Sources: Brines M. et al., PNAS (2008); van der Linden D. et al., PLoS ONE (2015); Niesters M. et al., Anesthesiology (2014)<\/em><br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-54509251\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>ARA-290 Research Areas<\/h2>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1506490510\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Neuroprotection and dorsal root ganglia (DRG)<\/h3>\n<p>One of the key areas of research for ARA-290 is <strong>neuroprotection at the level of the dorsal root ganglia (DRG)<\/strong> \u2014clusters of nerve cells (sensory neurons) located along the spinal cord. The DRGs are responsible for transmitting sensory signals, including pain. Preclinical studies have demonstrated the protective effect of ARA-290 on these neurons in models of peripheral neuropathy.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1347706890\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Research on Neuropathic Pain<\/h3>\n<p>Based on preclinical research, Araim Pharmaceuticals has initiated <strong>Phase 2 clinical trials<\/strong> focused on neuropathic pain associated with <strong>small fiber neuropathy (SFN)<\/strong> \u2014a form of peripheral neuropathy affecting small unmyelinated nerve fibers. Results from pilot clinical trials showed a reduction in neuropathic pain symptoms and an improvement in nerve fiber density (skin biopsy IENF density) compared to placebo.<br \/>\nThese results are preliminary and come from small studies. Their clinical relevance requires confirmation in larger randomized controlled trials.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-625626065\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Inflammatory Processes and Tissue Repair<\/h3>\n<p>ARA-290 is also being studied in the areas of inflammatory processes and tissue repair. Preclinical models demonstrate its anti-inflammatory effects through modulation of the cytokine response and a reduction in inflammatory cell infiltration. In a model of diabetic nephropathy, a protective effect on renal tissue was observed.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1463843147\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Clinical Research Context<\/h2>\n<p>Araim Pharmaceuticals has conducted several Phase 1 and 2 clinical trials with ARA-290 (cibinetide):<\/p>\n<ul>\n<li><strong>Phase 1:<\/strong> Demonstration of safety and tolerability in healthy volunteers. Confirmation of the absence of hematopoietic activity. <\/li>\n<li><strong>Phase 2 \u2013 Small Fiber Neuropathy (SFN):<\/strong> A pilot study documented a statistically significant reduction in neuropathic pain symptoms and an improvement in intraepidermal nerve fiber density (IENFD).<\/li>\n<li><strong>Phase 2 \u2013 Sarcoidosis with Neuropathy:<\/strong> The ARA-290 Study in Patients with Sarcoidosis Complicated by Small-Fiber Neuropathy.<\/li>\n<\/ul>\n<p>Important Notice: <strong>ARA-290 is not approved as a drug in the EU or the U.S.<\/strong> Clinical studies have not demonstrated sufficient efficacy to support regulatory approval for any indication. The product sold on jacked.sk is a research compound, not a drug.<br \/>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-564620898\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Comparison of ARA-290 vs. Erythropoietin (EPO)<\/h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Property<\/strong><\/td>\n<td><strong>Erythropoietin (EPO)<\/strong><\/td>\n<td><strong>ARA-290 (cibinetide)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>Receptor<\/strong><\/td>\n<td>Homodimeric EPOR (hematopoietic)<\/td>\n<td>IRR \/ TPCR (EPOR\u2013\u03b2c heterodimer)<\/td>\n<\/tr>\n<tr>\n<td><strong>Erythropoietic activity<\/strong><\/td>\n<td>YES \u2013 stimulation of erythrocyte production<\/td>\n<td>NO \u2013 no hematopoietic activity<\/td>\n<\/tr>\n<tr>\n<td><strong>Tissue-protective activity<\/strong><\/td>\n<td>Partial (via IRR)<\/td>\n<td>Primary function<\/td>\n<\/tr>\n<tr>\n<td><strong>Risk of Thrombosis<\/strong><\/td>\n<td>Increased with long-term use<\/td>\n<td>Not reported in Phase 1\u20132 studies<\/td>\n<\/tr>\n<tr>\n<td><strong>Clinical Use<\/strong><\/td>\n<td>Anemia associated with CKD, chemotherapy, and HIV<\/td>\n<td>In the research stage (Phase 2)<\/td>\n<\/tr>\n<tr>\n<td><strong>Usage on jacked.sk<\/strong><\/td>\n<td>N\/A (not in the catalog)<\/td>\n<td>For scientific research purposes only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-890374301\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Technical Specifications<\/h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Parameter<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>Chemical name<\/strong><\/td>\n<td>ARA-290 (cibinetide)<\/td>\n<\/tr>\n<tr>\n<td><strong>Origin<\/strong><\/td>\n<td>A cyclic peptide derived from erythropoietin (EPO)<\/td>\n<\/tr>\n<tr>\n<td><strong>Sequence length<\/strong><\/td>\n<td>11 amino acids (cyclic structure)<\/td>\n<\/tr>\n<tr>\n<td><strong>Molecular weight<\/strong><\/td>\n<td>~1,200 Da<\/td>\n<\/tr>\n<tr>\n<td><strong>CAS Number<\/strong><\/td>\n<td>1208243-50-8<\/td>\n<\/tr>\n<tr>\n<td><strong>Form<\/strong><\/td>\n<td>Lyophilized (freeze-dried) white powder<\/td>\n<\/tr>\n<tr>\n<td><strong>Contents per package<\/strong><\/td>\n<td>10 mg<\/td>\n<\/tr>\n<tr>\n<td><strong>Purity<\/strong><\/td>\n<td>\u2265 98% (HPLC-verified)<\/td>\n<\/tr>\n<tr>\n<td><strong>Recommended storage conditions<\/strong><\/td>\n<td>\u221220 \u00b0C, protected from light and moisture<\/td>\n<\/tr>\n<tr>\n<td><strong>Intended Use<\/strong><\/td>\n<td>For scientific research purposes only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-132634174\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Frequently Asked Questions About ARA-290<\/h2>\n<div class=\"accordion\">\n\t<div id=\"accordion-4138503226\" class=\"accordion-item\">\n\t\t<a id=\"accordion-4138503226-label\" class=\"accordion-title plain\" href=\"#accordion-item-what-is-ara-290,-and-how-is-it-related-to-erythropoietin?\" aria-expanded=\"false\" aria-controls=\"accordion-4138503226-content\">\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\" aria-hidden=\"true\"><\/i><\/button>\n\t\t\t<span>What is ARA-290, and how is it related to erythropoietin?<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-4138503226-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-4138503226-label\">\n\t\t\t\n<\/strong>ARA-290 (cibinetide) is an 11-amino acid cyclic peptide derived from a structural domain of erythropoietin (EPO). It was designed to activate the tissue-protective IRR receptor without stimulating erythropoiesis (the production of red blood cells).<br \/>\n\t\t<\/div>\n\t<\/div>\n\t\n\t<div id=\"accordion-2636856148\" class=\"accordion-item\">\n\t\t<a id=\"accordion-2636856148-label\" class=\"accordion-title plain\" href=\"#accordion-item-why-is-the-absence-of-erythropoietin-activity-of-interest-to-researchers?\" aria-expanded=\"false\" aria-controls=\"accordion-2636856148-content\">\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\" aria-hidden=\"true\"><\/i><\/button>\n\t\t\t<span>Why is the absence of erythropoietin activity of interest to researchers?<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-2636856148-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-2636856148-label\">\n\t\t\t\n<\/strong>Conventional EPO, when administered over the long term, increases hematocrit levels and the risk of thrombosis. ARA-290 does not exhibit these adverse effects (as confirmed in Phase 1\u20132 studies), which opens up possibilities for longer-term research into tissue protection without hematological concerns.<br \/>\n\t\t<\/div>\n\t<\/div>\n\t\n\t<div id=\"accordion-54115290\" class=\"accordion-item\">\n\t\t<a id=\"accordion-54115290-label\" class=\"accordion-title plain\" href=\"#accordion-item-in-what-clinical-trials-has-ara-290-been-tested?\" aria-expanded=\"false\" aria-controls=\"accordion-54115290-content\">\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\" aria-hidden=\"true\"><\/i><\/button>\n\t\t\t<span>In what clinical trials has ARA-290 been tested?<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-54115290-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-54115290-label\">\n\t\t\t\n<\/strong>Araim Pharmaceuticals has conducted Phase 2 trials for small fiber neuropathy (SFN) and sarcoidosis with neuropathy. Preliminary results were positive; however, ARA-290 has not been approved as a drug. Details are available on ClinicalTrials.gov.<br \/>\n\t\t<\/div>\n\t<\/div>\n\t\n\t<div id=\"accordion-1641654711\" class=\"accordion-item\">\n\t\t<a id=\"accordion-1641654711-label\" class=\"accordion-title plain\" href=\"#accordion-item-how-pure-is-ara-290-on-jacked.sk?\" aria-expanded=\"false\" aria-controls=\"accordion-1641654711-content\">\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\" aria-hidden=\"true\"><\/i><\/button>\n\t\t\t<span>How pure is ARA-290 on jacked.sk?<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-1641654711-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-1641654711-label\">\n\t\t\t\n<\/strong>ARA-290 from jacked.sk has a purity of \u226598%, verified by HPLC. A Certificate of Analysis (COA) is available upon request.<br \/>\n\t\t<\/div>\n\t<\/div>\n\t\n\t<div id=\"accordion-2709602152\" class=\"accordion-item\">\n\t\t<a id=\"accordion-2709602152-label\" class=\"accordion-title plain\" href=\"#accordion-item-how-should-ara-290-be-stored?\" aria-expanded=\"false\" aria-controls=\"accordion-2709602152-content\">\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\" aria-hidden=\"true\"><\/i><\/button>\n\t\t\t<span>How should ARA-290 be stored?<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-2709602152-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-2709602152-label\">\n\t\t\t\n<\/strong>Store unopened packages at \u221220 \u00b0C, protected from light and moisture. Avoid repeated thawing and freezing.<br \/>\n\t\t<\/div>\n\t<\/div>\n\t\n\t<div id=\"accordion-1801593601\" class=\"accordion-item\">\n\t\t<a id=\"accordion-1801593601-label\" class=\"accordion-title plain\" href=\"#accordion-item-is-ara-290-approved-as-a-drug?\" aria-expanded=\"false\" aria-controls=\"accordion-1801593601-content\">\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\" aria-hidden=\"true\"><\/i><\/button>\n\t\t\t<span>Is ARA-290 approved as a drug?<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-1801593601-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-1801593601-label\">\n\t\t\t\n<\/strong>No. ARA-290 (cibinetide) is not approved as a drug in the EU or the U.S. It is sold exclusively as a research compound for scientific purposes to individuals over the age of 18.<br \/>\n\t\t<\/div>\n\t<\/div>\n\t\n<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1750020023\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:#fe5000;border-width:1px 1px 1px 1px;\">\n\t<\/div>\n\t\t\t\n<h4>\u26a0\ufe0f Warning \u2013 Intended exclusively for research purposes<\/h4>\n<p><strong>All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes.<\/strong>  They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.<br \/>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1750020023 > .col-inner {\n  padding: 0.5rem 0.5rem 0.5rem 0.5rem;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>ARA-290 (cibinetide) is a cyclic 11-amino acid peptide derived from erythropoietin. It activates the tissue-protective IRR (Innate Repair Receptor) <strong>without stimulating red blood cell production<\/strong> \u2014it is precisely this selectivity that makes it a subject of research in neuroprotection, neuropathic pain, and tissue repair. <\/p>\n<ul>\n<li>Purity <strong>\u2265 98%<\/strong> \u2013 Each batch verified by HPLC; COA available upon request<\/li>\n<li>10 mg of lyophilized powder, store at \u221220 \u00b0C<\/li>\n<li>Shipped within 48 hours<\/li>\n<\/ul>\n","protected":false},"featured_media":7283,"template":"","meta":[],"product_brand":[],"product_cat":[137],"product_tag":[],"class_list":["post-7284","product","type-product","status-publish","has-post-thumbnail","product_cat-research-on-tissue-regeneration-and-healing","first","instock","sale","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/product\/7284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/media\/7283"}],"wp:attachment":[{"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/media?parent=7284"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/product_brand?post=7284"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/product_cat?post=7284"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/dev.jacked.sk\/en\/wp-json\/wp\/v2\/product_tag?post=7284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}